- Keine Daten
Deutsch
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
The Asia Optoelectronic Expo 2025 (APE 2025) will be held from February 26 to 28, 2025 at the Marina Bay Sands Convention and Exhibition Centre in Singapore. It covers products such as information and communication, optics, lasers, infrared, sensing, display, quantum, and is a one-stop optoelectronic comprehensive platform for the optoelectronic industry and application fields; The exhibition focu...
Organic solid-state lasers (OSLs) are expected to achieve widespread applications due to their flexibility, tunability, and efficiency. However, they are difficult to manufacture and require over 150.000 possible experiments to find successful new materials, and discovering them will be a work of several lifetimes. In fact, according to data from the University of Toronto in Canada, only 10-20 new...
Researchers from Huazhong University of Science and Technology, AVIC Xi'an Aircraft Design and Research Institute, AVIC Xi'an Aircraft Industry Group Co., Ltd., Shanghai Aerospace Equipment Manufacturing General Factory Co., Ltd., State Key Laboratory of Aircraft Control Integration Technology, Beijing Xinghang Electromechanical Equipment Co., Ltd. and Nanjing Yingigma Automation Co., Ltd. reporte...
Recently, Scientific Photonics, a supplier of silicon photonic integrated circuits (PICs) headquartered in Grenoble, announced that it has successfully integrated III-V-DFB lasers and amplifiers with standard silicon photonic technology into the production process of Tower Semiconductor.By utilizing proprietary technology and standard silicon photonics, Scientific Photonics has achieved full inte...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...